Ozempic Under Fire: Manufacturer Faces $2 Billion in Lawsuits Over Alleged Side Effects

Ozempic, a drug originally approved to treat type 2 diabetes and now widely used as a weight-loss aid, is at the center of mounting legal battles. The manufacturer, Novo Nordisk, faces more than $2 billion in Ozempic lawsuits alleging serious side effects, such as stomach paralysis and vision loss. 

Ozempic: Marketed As a Dual-Purpose Drug

Ozempic, known generically as semaglutide, belongs to a class of medications called GLP-1 receptor agonists. These drugs work by mimicking the effects of a hormone that regulates blood sugar levels and appetite. Originally approved to help individuals manage diabetes, Ozempic is designed to stimulate insulin secretion in response to elevated blood sugar levels, thereby helping to lower glucose levels in the bloodstream. 

However, Ozempic has been increasingly prescribed off-label for weight loss, leading to the drug’s rise in popularity. By acting on the brain’s appetite centers, Ozempic can reduce hunger, leading to decreased food intake and subsequent weight loss.

Reports of Potential Side Effects from Ozempic

Ozempic’s effectiveness in facilitating weight loss has attracted attention from various demographics, including individuals without diabetes. Celebrity endorsements and social media trends have further fueled its demand, making it a go-to option for many seeking quick weight loss solutions. Despite its potential benefits, however, Ozempic has been linked to a range of serious health complications. Among the side effects allegedly associated with Ozempic are:

• Gastroparesis: A condition where the stomach cannot empty properly, leading to nausea, vomiting, and abdominal pain.
• Vision Loss: Specifically, a condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can result in sudden and irreversible vision impairment.
• Gallbladder Issues: Including gallstones and acute cholecystitis, which can lead to severe abdominal pain and require surgical intervention.

Ozempic Lawsuits Against Novo Nordisk

As reports of these alleged Ozempic side effects have surfaced across the country, numerous lawsuits have been filed against Novo Nordisk, the manufacturer of Ozempic. Plaintiffs suing the drug maker argue that the company failed to adequately warn consumers and healthcare providers about the potential risks associated with Ozempic, particularly when used for weight loss.

As of August 2025, nearly 2,000 product liability lawsuits naming GLP-1 medications like Ozempic have been consolidated into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania. Legal analysts predict that the total liability could exceed $2 billion, reflecting the severity of the claims and the number of affected individuals.

Medical Evidence Supporting the Ozempic Claims

Recent studies have bolstered the growing number of claims against Ozempic, revealing a concerning association between the diabetes and weight loss drug and various health complications. For instance:

• A case report published in the Journal of Investigative Medicine High Impact Case Reports highlights two cases of medication-induced gastroparesis that were originally diagnosed as diabetic gastroparesis.
• A 2024 study published in JAMA Ophthalmology reveals that patients taking semaglutide-based drugs like Ozempic and Wegovy have an increased risk of developing NAION. 

In response to growing concerns about alleged Ozempic side effects, the U.S. Food and Drug Administration (FDA) in 2023 mandated labeling changes for Ozempic, highlighting the potential risks of gastrointestinal disorders.

What Lies Ahead for Ozempic Litigation?

As the GLP-1 MDL progresses in federal court, several key developments are anticipated:

• Bellwether Trials: Representative claims will be selected for early trials, which could set precedents for future claims.
• Expert Testimony: Medical professionals will provide insights on causation and the safety of Ozempic and other GLP-1 drugs.
• Settlement Negotiations: If early trials favor plaintiffs, Novo Nordisk may consider negotiating settlements to resolve Ozempic claims.

The outcomes of these lawsuits could have significant implications for patients currently using Ozempic or considering it for diabetes or weight loss management. If the courts find in favor of the plaintiffs in the Ozempic litigation, it may lead to increased scrutiny of GLP-1 receptor agonists and their safety profiles.

The Broader Context: Public Health Implications

The controversies surrounding Ozempic and other GLP-1 medications highlight the need for comprehensive patient education regarding the potential health risks associated with pharmaceutical drugs. As the popularity of weight-loss drugs continues to rise across the U.S., healthcare providers must communicate potential side effects effectively.

For patients currently using Ozempic, healthcare professionals recommend:

• Regular check-ups to monitor gastrointestinal health and vision.
• Reporting any persistent symptoms, such as nausea or changes in eyesight.
• Considering lifestyle changes as safer, long-term alternatives for weight management.

What Is the Future of Ozempic? 

The situation surrounding Ozempic is a complex interplay of medical efficacy, patient safety, and corporate responsibility. As the legal battles unfold and more evidence emerges regarding the potential health risks associated with Ozempic, the focus remains on patient safety and the responsibilities of pharmaceutical companies. The ongoing lawsuits against Novo Nordisk serve as a reminder of the importance of transparency in drug marketing and the need for thorough risk assessments.